Processa Pharmaceuticals, Inc.PCSAEarnings & Financial Report
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutic solutions for patients with high unmet medical needs. Its core product pipeline targets rare diseases, gastrointestinal disorders, and dermatological conditions, with primary operational focus on the North American and European healthcare markets.
PCSA Q3 FY2023 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-2.2M
Net Profit
$-2.1M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-1.54
Processa Pharmaceuticals, Inc. Q3 FY2023 Financial Summary
Processa Pharmaceuticals, Inc. reported revenue of $0 for Q3 FY2023, with a net profit of $-2.1M (up 65.4% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-2.1M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q3 FY2023 |
Processa Pharmaceuticals, Inc. Annual Revenue by Year
Processa Pharmaceuticals, Inc. annual revenue history includes year-by-year totals (for example, 2022 revenue was $0).
Processa Pharmaceuticals, Inc. Quarterly Revenue & Net Profit History
Processa Pharmaceuticals, Inc. results over the last 7 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2023 | $0 | — | $-2.1M | N/A |
| Q2 FY2023 | $0 | — | $-2.6M | N/A |
| Q1 FY2023 | $0 | — | $-4.0M | N/A |
| Q4 FY2022 | $0 | — | $-13.0M | N/A |
| Q3 FY2022 | $0 | — | $-6.0M | N/A |
| Q2 FY2022 | $0 | — | $-5.2M | N/A |
| Q1 FY2022 | $0 | — | $-3.2M | N/A |
Income Statement
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Balance Sheet
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | |
|---|---|---|---|---|---|---|---|
| Assets | $24.3M | $21.7M | $18.6M | $8.6M | $12.4M | $10.1M | $8.1M |
| Liabilities | $1.1M | $1.6M | $1.4M | $1.1M | $2.3M | $930741 | $914847 |
| Equity | $23.2M | $20.1M | $17.2M | $7.5M | $10.1M | $9.2M | $7.2M |
Cash Flow
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $-1.8M | $-2.3M | $-3.0M | $-2.5M | $-2.1M | $-2.1M | $-1.8M |